Restrictive (as Pulmonary Fibrosis) vsObstructive Disease (COPD)-September-2015

Restrictive (as Pulmonary Fibrosis) vs.Obstructive Disease (COPD) Although there are hundreds of diseases that can affect the lungs, we do broadly describe almost all lung disease as either restrictive or obstructive. The obstructive group of diseases, primarily emphysema and chronic bronchitis, are also known as Chronic Obstructive Pulmonary Disease or COPD. It wasn’t that long…

Fibrosis File – March 2019

Fibrosis File Be sure to check out the latest videos from the PF War- riors  meetings  and   seminars at https://pfwarrior.com/video/ Research News Physicians at the University of Texas Health Science Center at Tyler have devel- oped a drug that could reverse scarring in the lungs that occurs in pulmonary fibrosis. A fragment of a protein,…

Fibrosis File – January 2017

Fibrosis File Pulmonary Fibrosis News brings us last year’s big stories in the world of Pulmonary Fibrosis. Here is the countdown! Esbriet Found to Reduce Idiopathic Pulmonary Fibrosis Progression across Disease Stages An Italian study found that people with idiopathic pulmonary fibrosis (IPF) might benefit from Esbriet (pirfenidone) treatment, regardless of their disease stage and…

Fibrosis File – January 2015

Fibrosis File The Pulmonary Fibrosis Foundation (www.pulmonaryfibrosis.org) has an Inter­ net Patient Support Community called Inspire. It is a great place where people can share helpful tips and their concerns at www.inspire.com. Among the postings: tillI lsove to cook and having  just gone through the holidays, I thought I would share a few I have…

Fibrosis File – March 2014

Fibrosis File We have been following pharmaceuti- cal company InterMune and its battle to get pirfenidone approved in the United States. The drug has been available to treat idiopathic pulmonary fibrosis (IPF) in Europe, Canada, Japan, South Korea, China, India, Argentina and Mexico where it is known as Esbriet. In a surprise move in May…

Fibrosis File-November-2013

    Fibrosis File Exciting New IPF Research! Reporting in Modern Pathology, Ohio State University researchers have found Idiopathic Pulmonary Fibrosis (IPF) might be caused by a virus. Evidence of the pathogen, herpesvirus saimiri, was found in all tissue samples from patients with IPF, but in none of those from patients with fibrosis with a…

Fibrosis File-July-2013

    Fibrosis File Matt from Florida recently asked if there are any “specific” exercises that target the conditioning needs unique to those with pulmonary fibrosis (PF). Mark Mangus answers, The main problem or limita­ tion to exercising with pulmonary fibrosis is shortness of breath. You will have to do extra work to move sufficient…

Fibrosis File-November-2012

Fibrosis File The Coalition for Pulmonary Fibrosis (CPF) and the Westie Foundation of America (WFA) have formed a strategic alliance to fight Pulmonary Fibrosis. The WFA is a canine organization focused on the health of West Highland terriers or “Westies”. Interstitial Pulmonary Fibrosis (IPF) is known in the dog world as Westie lung disease. Researchers…

Fibrosis File – January 2011

Fibrosis File  IPF Medication and Research News Gilead Sciences Inc. is halting the Phase III clinical trial of Ambrisentan in patients with idiopathic pulmonary fibrosis (IPF) “due to lack of efficacy.” The biopharma- ceutical company said the decision follows an analysis of efficacy and safety data “which did not show evidence of a treatment benefit…

Fibrosis File – September 2010

Fibrosis File Orphan Drug Status Granted In early September, the FDA granted orphan drug status to STX-100, an investigational, humanized monoclonal antibody used in the treatment of idiopathic pulmonary fibrosis (IPF). STX-100 targets a key pathway in the initiation and progression of pulmonary fibrosis, according to manufacturer Stromedix Inc. There are currently no FDA-approved treatments…